Pillstats
Rx only · Injection · Intravenous

Nelarabine

Brands: Arranon · Nelarabine

11 ACTIVE SUPPLIERS — US
openFDA · updated weekly
US15 NDCs
11 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
ATCL01BB07
RxCUI (US)274771
US makers12 labelers
Packages25
DEA / ScheduleNone

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

47931401862025 Q12025 Q22025 Q32025 Q42026 Q1
126
Rx · 2026 Q1
19K
Units dispensed
-22%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it11 active · 1 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
Zydus Pharmaceuticals USA Inc.unknown4SUPPLYING
Alembic Pharmaceuticals Limitedunknown4SUPPLYING
Shorla Oncology Inc.unknown3SUPPLYING
Novadoz Pharmaceuticals LLCunknown2SUPPLYING
Amneal Pharmaceuticals LLCunknown2SUPPLYING
XGen Pharmaceuticals DJB, Inc.unknown2SUPPLYING
Dr.Reddy's laboratories Limitedunknown2SUPPLYING
Zydus Lifesciences Limitedunknown2SUPPLYING
Gland Pharma Limitedunknown1SUPPLYING
Meitheal Pharmaceuticals Inc.unknown1SUPPLYING
Sandoz Incunknown1SUPPLYING
Novartis Pharmaceuticals Corporationunknown1EXITED 2026

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Feb 13, 2025
    RECALLRecall (Class II): Nelarabine Injection, 250mg/50mL, (5mg/mL), packaged in: a) 50 mL Single-Dose Vial, NDC 70710-1726-1; b) 6 x 50 mL Sin…

    Failed Impurities/Degradation Specifications — Recalling firm: Zydus Pharmaceuticals (USA) Inc — USA Nationwide

  • Feb 13, 2025
    RECALLRecall (Class II): Nelarabine Injection, 250mg/50mL, (5mg/mL), packaged in: a) 50 mL Single-Dose Vial, NDC 70710-1839-1; b) 6 x 50 mL Sin…

    Failed Impurities/Degradation Specifications — Recalling firm: Zydus Pharmaceuticals (USA) Inc — USA Nationwide